A phase 3b, multicenter, randomized, open-label, active-controlled study to compare the efficacy and safety of guselkumab versus risankizumab in the treatment of participants with moderately to severely active Crohn’s Disease
Moderately to severely active Crohn's Disease
Experimental: Guselkumab Participants will receive guselkumab induction dose subcutaneously (SC) at Weeks 0, 4, and 8 followed by guselkumab maintenance dose SC once every 4 weeks (q4w) from Week 12 through Week 52. Experimental: Risankizumab Participants will receive risankizumab induction dose intravenously (IV) at Weeks 0, 4, and 8 followed by risankizumab maintenance dose SC once every 8 weeks (q8w) from Week 12 through Week 52.
1. Has CD or fistulizing Crohn's Disease (CD) of at least 12 weeks’ duration, with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, and/or endoscopy 2. Have moderately to severely active CD, defined as baseline Crohn’s Disease Activity Index (CDAI) score greater than or equal to (>=) 220 but less than or equal to (<=) 450 3. Baseline endoscopic evidence of active ileal and/or colonic CD as assessed by central endoscopy reading at the screening endoscopy defined as a screening Simple Endoscopic Score for Crohn’s Disease (SES CD) >= 4 (for participants with isolated ileal disease) or >= 6 (for participants with colonic or ileocolonic disease), based on the presence of ulceration in any 1 of the 5 ileocolonic segments, resulting in the following specified ulceration component scores: a. A minimum score of 1 for the component of “size of ulcers” AND b. A minimum score of 1 for the component of “ulcerated surface" 4. In the opinion of the investigator, participant’s disease is appropriate to treat with the maintenance dosing regimens utilized in the study 5. Adhere to the requirements for concomitant medications for the treatment of CD as mentioned in the protocol
1. Has complications of CD such as symptomatic strictures or stenoses, short gut syndrome, active draining stoma or significant fistulizing disease or any other manifestation anticipated to require surgery within the next year, could preclude the use of the CDAI to assess response to therapy, or would possibly confound the ability to assess the effect of treatment with guselkumab or risankizumab 2. Currently has or is suspected to have an abscess 3. Has an active fistula during screening or at Week 0 with an anticipated need for surgery 4. Has had any kind of bowel resection within 24 weeks, or any other intraabdominal or other major surgery within 12 weeks, before first dose of study intervention 5. Currently has a malignancy or has a history of malignancy within 5 years before screening